Clinscience Digitizes Clinical Research by Investing in EXOM Group

Published on: 

Clinscience, on September 15th signed an investment agreement to acquire 60% of the digital CRO—EXOM Group. Headquartered in Milan, EXOM carries out its activities in the design, supervision, monitoring and management of Clinical Trials based on its own digital eco-system of more than 20 applications unified in the multi-modular platform Genius Suite.

EXOM Group's proprietary Genius Suite system will allow Clinscience to continue its digital transformation and conduct Clinical Trials with a focus on the needs of both Investigators and Patients and ultimately Sponsors.


More about Clinscience’s investment